All In Biotech

Free tool

FAERS Monitor: Rapiblyk

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217202 or its brand name (Rapiblyk, Landiolol Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

84

Serious

81

96% of reports

Hospitalization

56

Death reported

12

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective35
  • off label use12
  • bradycardia8
  • ventricular fibrillation7
  • condition aggravated6
  • drug ineffective for unapproved indication6
  • atrial fibrillation5
  • cardiac failure5
  • hypotension5
  • product use in unapproved indication5
  • cardiogenic shock4
  • electrocardiogram qt prolonged4
  • stress cardiomyopathy4
  • tachycardia4
  • torsade de pointes4

Reports by year received

View as table
YearReports
20101
20111
20132
20141
20154
20161
20172
20182
20191
20204
202112
202225
202414
20259
20265

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,075 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
stress cardiomyopathySignal4172.466.2521
ventricular fibrillationSignal7157.977.7940
torsade de pointesSignal4127.849.1384
cardiogenic shockSignal469.826.8207
bradycardiaSignal837.819.5251
electrocardiogram qt prolongedSignal427.910.779
drug ineffective for unapproved indicationSignal627.412.7128
cardiac failureSignal515.66.755
atrial fibrillationSignal512.95.544
tachycardiaSignal411.34.328
drug ineffectiveSignal356.65.2173
hypotensionSignal56.22.717
product use in unapproved indicationSignal55.12.213
condition aggravatedSignal64.92.315
off label useSignal123.42.019

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.